Figure 2 : MRCs support MuSCs in de novo myofibre formation.

From: Bioengineered constructs combined with exercise enhance stem cell-mediated treatment of volumetric muscle loss

Figure 2

(a) Representative FACS plot of MRCs. Lower limb muscles were dissected and digested to obtain a mononucleated cellular suspension. These cells were marked using cell specific surface antigens as described in the ‘Results’ and in the ‘Methods’ sections and were analysed using FACS. Five populations were isolated: muscle stem cells (MuSCs), hematopoietic cells (HCs), endothelial cells (ECs), fibro-adipogenic progenitor cells (FAPs) and fibroblast-like cells (FLCs). The relative percentages of each cell population are 10%, 25%, 39%, 8% and 18%, respectively (n=6). (b) Quantified results of in vitro bioluminescence generated from cultured bioconstructs containing Luc+ MuSCs, either alone (MuSC+/MRC) or in combination with Luc MRCs (MuSC+/MRC+). Bioconstructs were cultured for three days, and bioluminescence was measured each day (n=4). (c) Representative images of bioluminescence measured from mice 10 days after transplantation of bioconstructs in left TA muscles immediately following VML injury (d) Quantified results of non-invasive imaging of transplanted bioconstructs. Bioconstructs with no cells (MuSC/MRC), Luc+ MuSCs (MuSC+/MRC), or Luc+ MuSCs in addition to Luc MRCs (MuSC+/MRC+) were transplanted into TA muscles that had received VML injuries. Bioluminescence was measured 10 days following transplantation (n=4). Data are±s.e.m. For statistical analysis, t-tests were used. *P<0.05; **P<0.001.